Last update 22 Mar 2025

pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine(University of Washington)

Overview

Basic Info

Drug Type
DNA vaccine, Therapeutic vaccine
Synonyms-
Target
IGFBP2
Action
modulators
Mechanism
IGFBP2 modulators(IGF binding protein-2 modulators)
Therapeutic Areas
NeoplasmsEndocrinology and Metabolic DiseaseUrogenital Diseases+ [1]
Active Indication-
Inactive Indication
Ovarian Epithelial CarcinomaOvarian Germ Cell CancerRecurrent ovarian cancer
Originator Organization
University of WashingtonUniversity of Washington
Active Organization-
Inactive Organization
University of WashingtonUniversity of Washington
Drug Highest PhasePendingPhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine(University of Washington)
NCT01322802
/ CompletedPhase 1IIT
A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine Encoding the Amino Acids 1-163 of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in Patients With Advanced Ovarian Cancer
100 Clinical Results associated with pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine(University of Washington)
Login to view more data
100 Translational Medicine associated with pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine(University of Washington)
Login to view more data
100 Patents (Medical) associated with pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine(University of Washington)
Login to view more data
100 Deals associated with pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine(University of Washington)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Ovarian Epithelial CarcinomaPhase 1
United States
University of WashingtonUniversity of Washington
06 Mar 2012
Ovarian Germ Cell CancerPhase 1
United States
University of WashingtonUniversity of Washington
06 Mar 2012
Recurrent ovarian cancerPhase 1
United States
University of WashingtonUniversity of Washington
06 Mar 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT01322802 (ASCO 12016 | ASCO 22016)
ManualManual
Phase 1
Ovarian Cancer
25
bqbnufespm(qndmoseamn) = Fatigue (12%) and injection site reactions (12%) vfbhnttzpx (actdcxhfmi )
Positive
06 Jun 2016
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free